CClinicalTrials.gg
Sign In
CompletedNCT02042300IRIS XPEDITIONUpdated Dec 29, 2025

XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice

An observational study in Percutaneous Transluminal Coronary Angioplasty and Coronary Artery Disease, sponsored by Seung-Jung Park. Completed at 26 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Seung-Jung Park · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4,000
Ages
19 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate effectiveness and safety of XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice

02

Conditions studied

  • Percutaneous Transluminal Coronary Angioplasty
  • Coronary Artery Disease

Keywords

  • XIENCE Xpedition
  • Routine Clinical Practice
  • Alpine
  • Sierra
03

In context

Coronary Artery Disease

5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.

This study's enrollment of 4,000 is above the median of 336 across 1,947 observational studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Seung-Jung Park is the lead sponsor of 82 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with XIENCE Xpedition or Alpine or Sierra stent

Inclusion criteria

  • Age 19 and more
  • Intervention with XIENCE Xpedition or Alpine or Sierra everolimus eluting coronary stent
  • Agreed with written informed consent form

Exclusion criteria

Exclusion Criteria:

  • Intervention with XIENCE Xpedition or Alpine or Sierra everolimus eluting coronary stent and other drug eluting stent at the same time
  • Life expectancy of 1year and under
  • Cardiac shock
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4,000 participants (actual)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • IRIS-Xpedition/Alpine/Sierra Cohort

    XIENCE Xpedition/Alpine/Sierra

    Device: XIENCE Xpedition/Alpine/Sierra

Interventions

  • DeviceXIENCE Xpedition/Alpine/Sierra
06

What researchers measure

Primary outcomes

  1. Composite event rate

    Death, non fatal myocardial infarction, Target Vessel Revascularization

    Time frame: 1year

Secondary outcomes

  1. All death

    Time frame: 5year

  2. Cardiac death

    Time frame: 5year

  3. Myocardial infarction

    Time frame: 5year

  4. Composite event of death or myocardial infarction

    Time frame: 5year

  5. Composite event of cardiac death or myocardial infarction

    Time frame: 5year

  6. Target Vessel revascularization

    Time frame: 5year

  7. Target lesion revascularization

    Time frame: 5year

  8. Stent thrombosis by an Academic Research Consortium (ARC) criteria

    Time frame: 5year

  9. Stroke

    Time frame: 5year

  10. procedural success

    defined as less than 30% residual stenosis at the completion of procedure without death or Q wave myocardial infarction or urgent revascularization participants will be followed for the duration of hospital stay, an expected average of 3days.

    Time frame: 3day

07

Study locations

26 sites
  • Hallym University Sacred Heart Hospital
    Anyang, South Korea
  • Soon Chun Hyang University Hospital Bucheon
    Bucheon-si, South Korea
  • Soon Chun Hyang University Hospital Cheonan
    Cheonan, South Korea
  • Gangwon National Univ. Hospital
    Chuncheon, South Korea
  • Daegu Catholic University Medical Center
    Daegu, South Korea
  • Keimyung University Dongsan Medical Center
    Daegu, South Korea
  • Yeungnam University Medical Center
    Daegu, South Korea
  • The Catholic University of Korea, Daejeon ST. Mary's Hospital
    Daejeon, South Korea
  • Gangneung Asan Hospital
    Gangneung, South Korea
  • Chonnam National University Hospital
    Gwangju, South Korea
  • Gachon University Gil Hospital
    Incheon, South Korea
  • Inha University Hospital
    Incheon, South Korea
  • ChonBuk National University Hospital
    Jeonju, South Korea
  • Kwangju Christian Hospital
    Kwangju, South Korea
  • Dong-A Medical Center
    Pusan, South Korea
  • Inje University HAEUNDAE Paik Hospital
    Pusan, South Korea
  • Inje University Pusan Paik Hospital
    Pusan, South Korea
  • Pusan National University Hospital
    Pusan, South Korea
  • Asan Medical Center
    Seoul, South Korea
  • Korea University Guro Hospital
    Seoul, South Korea
  • Seoul Veterans Hospital
    Seoul, South Korea
  • The Catholic University of Korea Seoul St. Mary's Hospital
    Seoul, South Korea
  • The Catholic University of Korea, Yeouido St. Mary's Hospital
    Seoul, South Korea
  • The Catholic University of Korea Uijeongbu St. Mary's Hospital
    Uijeongbu-si, South Korea
  • Ulsan University Hospital
    Ulsan, South Korea
  • Pusan National University Yangsan Hospital
    Yangsan, South Korea
08

References and documents

Individual participant data

Plan to share: No — This is not a publicly funded trial.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02042300
Lead sponsor
Seung-Jung Park
Collaborators
CardioVascular Research Foundation, Korea, Abbott
Responsible party
Seung-Jung Park (MD,PhD, Asan Medical Center) — Sponsor-investigator
First posted
Jan 22, 2014
Start date
May 2014
Primary completion
Jul 2020
Completion
Aug 30, 2024
Last update
Dec 29, 2025

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Coronary Artery Disease→

Other studies from this sponsor

Seung-Jung Park

Start the discussion